Cell & Gene The Podcast Videocast

1. How Precision Oncology Is Redefining Cancer Drug Development with Aprea Therapeutics' Dr. Oren Gilad 7/15/2026

   Episode 133 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Aprea Therapeutics' CEO, Dr. Oren Gilad. They cover the evolution of precision oncology, the science of synthetic lethality, and how Aprea is developing next-generation therapies that target cancer's unique genetic vulnerabilities while improving safety and efficacy.

2. Exploring Dendritic Cell Therapy for Solid Tumors with Diakonos Oncology's Jay Hartenbach 6/30/2026

   Episode 132 of Cell & Gene: The Podcast features Host, Erin Harris' conversation with Diakonos Oncology's President and COO, Jay Hartenbach, to explore how the company is advancing a patient-derived dendritic cell therapy designed to generate a stronger immune response against difficult-to-treat solid tumors, including glioblastoma, pancreatic cancer, and refractory melanoma.

3. Cell & Gene: The Podcast Presents: Better Biopharma's Editors' Roundtable — A Midyear Look at the 2026 Life Sciences Industry 6/15/2026

   For episode 131 of Cell & Gene: The Podcast, we’re sharing a recent "Better Biopharma" roundtable that Erin Harris had the opportunity to join alongside her Life Science Connect editorial colleagues.

4. Why In Vivo Therapies Are Moving Toward the Clinic with Ascidian Therapeutics' Dr. Mike Ehlers 6/9/2026

   This is episode 3 of our in vivo-focused special series of Cell & Gene: The Podcast. Here, Ascidian Therapeutics' Founder, President, and CEO Mike Ehlers, M.D., Ph.D., explains how the company is advancing a new class of genetic medicines built on RNA exon editing to durably correct disease at the transcript level without permanently altering DNA.

5. Reimagining In Vivo Gene Editing Through Base Editing and Targeted Delivery with Beam Therapeutics' Gopi Shanker, Ph.D. 6/2/2026

   In episode 2 of this four-part in vivo-focused special series of Cell & Gene: The Podcast, Host Erin Harris sits down with Gopi Shanker, Ph.D., Chief Scientific Officer at Beam Therapeutics, for an in-depth conversation on the rapidly evolving landscape of in vivo gene editing and precision genetic medicines.

6. Advancing CAR T for Drug-Free Remission in Autoimmune Disease with Kyverna Therapeutics' Dr. Naji Gehchan 6/2/2026

   In episode 130 of Cell & Gene: The Podcast, Dr. Naji Gehchan, Chief Medical and Development Officer at Kyverna Therapeutics, joins Host Erin Harris to outline the company’s mission to apply CAR T-cell therapy beyond oncology to treat severe autoimmune diseases, highlighting promising Phase 2 data from its investigational therapy, Miv-cel, in stiff person syndrome (SPS).

7. The Future of In Vivo Gene Editing and Clinical Translation with Precision Biosciences' Cassie Gorsuch, Ph.D. 5/26/2026

   In this first episode our in vivo-focused special series of Cell & Gene: The Podcast, Host Erin Harris speaks with Cassie Gorsuch, Ph.D., CSO at Precision Biosciences, about the rapid evolution of in vivo gene editing and the scientific, translational, and regulatory hurdles shaping the field.

8. Redefining CAR-T Timing and Patient Access with Allogene Therapeutics' Dr. Zachary Roberts 5/19/2026

   In episode 129 of Cell & Gene: The Podcast, Host Erin Harris reconnects with Zachary Roberts, M.D., Ph.D., EVP of Research & Development and Chief Medical Officer at Allogene Therapeutics, to explore how allogeneic CAR-T is evolving from a scalability promise into an earlier-line, potentially curative intervention.

9. Building Integrated cGMP Systems for Autologous Cell Therapies with MassGen's Tatyana Matveeva, Ph.D. 5/6/2026

   In episode 128, Host Erin Harris talks to Tatyana Matveeva, Ph.D., Director of cGMP Operations at George A. "Doc" Lopez, MD Laboratory for Regenerative Cell Therapy, Harvard Medical School and Massachusetts General Hospital, about leading cGMP operations within an integrated ecosystem at Harvard Medical School and Massachusetts General Hospital, where manufacturing, research, and neurosurgery coexist.

10. Rewriting Disease Biology Through LSD1 Inhibition with Oryzon's Carlos Buesa, Ph.D. 4/22/2026

    On Episode 127 of Cell & Gene: The Podcast, Carlos Buesa, Ph.D., Founder and Chairman of the Board at Oryzon talks to Host Erin Harris about how targeting LSD1 is unlocking new treatment approaches across oncology, CNS disorders, and sickle cell disease, with promising early clinical data and a strategy grounded in precision epigenetics.